Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market
- The 12-month clinical validation study (NCT02453776) data demonstrated the reduction “switching” from lower cost infliximab to more expensive biologics by 66%. Also- similar studies are ongoing in 9 countries on 3 continents
- The results were already presented at ECCO- Copenhagen- Mar 2019 and DDW- San Diego- May 2019 and the Baysient pipeline includes CDS for 25 FDA approved anti-inflammatory biologics. The HCPs using iDose software's CDS reduced the cost $726-000 per 100 patients
- The iDose algorithm is a cloud base SaaS and is HIPAA-compliant- compatible with EMRs offered in the US and Canada- combines the PK data with Bayesian learning (non-AI machine learning) and forecasting- also enables the physicians to understand how to keep the amount of drug in patient’s body from falling below the physician-selected target
Click here to read full press release/ article | Ref: PR Newswire | Image: Behance
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com